p2Ca | Cytiva思拓凡-Whatman滤纸滤膜滤器

p2Ca;

p2Ca是8聚体肽，是天然加工并呈递给Ld同种异体T细胞克隆2C的配体。

p2Ca Chemical Structure

CAS No. : 142606-55-1

规格	价格	是否有货
1 mg	￥2200	询问价格货期
5 mg	￥8000	询问价格货期

* Please select Quantity before adding items.

生物活性

p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.

体外研究
(In Vitro)

p2Ca and QL9 peptides assume distinct conformations when bind to Ld and, furthermore, demonstrate that there is flexibility in peptide binding within the MHC class I cleft. Ld antigenic peptide p2Ca (LSPFPFDL) is 8-mer that lack the proline at position 2 and thus use alternative amino-terminal anchors. The p2Ca octamer is identified as the ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C^[1]. p2Ca, is immunodominant in allorecognition of the murine MHC class I molecule H-2Ld. The majority of Ld-alloreactive T-cell clones are specific for Ld-p2Ca and this immunodominance is not due to peptide cross-reactivity^[2]. p2Ca is a ubiquitously expressed self-peptide. p2Ca is derived from the mouse mitochondrial enzyme α-ketoglutarate dehydrogenase. p2Ca is present in every tissue of BALB/c mice that has been examined, including the spleen and thymus. It is also expressed by mouse tumor cell lines such as the mastocytoma P815. CTL derived in vitro recognize specifically the p2Ca/L d complex and use Vβ8 regions predominantly. The cultured cells lyse target cells with lower levels of p2Ca than the levels used for induction. This result suggests that it may be possible to use peptides at high concentrations to elicit CTL that react with endogenous levels of a peptide/class I complex^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

BALB/c mice, coinjected with a syngeneic BALB/c myeloma and exogenous p2Ca, are able to reject the tumor. The p2Ca/L d system may thus provide a model for evaluating the parameters for effective immunotherapy with tumor-associated peptides^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

935.07

Formula

C₄₇H₆₆N₈O₁₂

CAS 号

142606-55-1

Sequence

Leu-Ser-Pro-Phe-Pro-Phe-Asp-Leu

Sequence Shortening

LSPFPFDL

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility

In Vitro:;

H₂O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

;	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3.;;Recommended solution:

Overall charge of peptide	Details
Negative (lt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH₄OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0)	1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

参考文献

[1]. Hornell TM, et al. Peptide length variants p2Ca and QL9 present distinct conformations to L(d)-specific T cells. J Immunol. 2001 Oct 15;167(8):4207-14.

[2]. Connolly JM, et al. The peptide p2Ca is immunodominant in allorecognition of Ld by beta chain variable region V beta 8+ but not V beta 8- strains. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11482-6.

[3]. Tjoa BA, et al. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection. Cancer Res. 1994 Jan 1;54(1):204-8.

Animal Administration ^[3]	Mice: The effectiveness of self-peptide treatment is evaluated using a syngeneic system with the BALB/c derived myeloma Sp2/0. B2 [an Ld transfectant of Sp2/0 (19)] is incubated for the indicated times with 3 or 30 μM p2Ca or without p2Ca. A binding assay with ¹²⁵I-labeled anti-Ld antibody 28-14-8 is performed^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Hornell TM, et al. Peptide length variants p2Ca and QL9 present distinct conformations to L(d)-specific T cells. J Immunol. 2001 Oct 15;167(8):4207-14. [2]. Connolly JM, et al. The peptide p2Ca is immunodominant in allorecognition of Ld by beta chain variable region V beta 8+ but not V beta 8- strains. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11482-6. [3]. Tjoa BA, et al. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection. Cancer Res. 1994 Jan 1;54(1):204-8.

Animal Administration
^[3]

Mice: The effectiveness of self-peptide treatment is evaluated using a syngeneic system with the BALB/c derived myeloma Sp2/0. B2 [an Ld transfectant of Sp2/0 (19)] is incubated for the indicated times with 3 or 30 μM p2Ca or without p2Ca. A binding assay with ¹²⁵I-labeled anti-Ld antibody 28-14-8 is performed^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Hornell TM, et al. Peptide length variants p2Ca and QL9 present distinct conformations to L(d)-specific T cells. J Immunol. 2001 Oct 15;167(8):4207-14.

[2]. Connolly JM, et al. The peptide p2Ca is immunodominant in allorecognition of Ld by beta chain variable region V beta 8+ but not V beta 8- strains. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11482-6.

[3]. Tjoa BA, et al. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection. Cancer Res. 1994 Jan 1;54(1):204-8.